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Abstract  
 prostatic cancer is a malignant neoplasm characterized by elevated level 7-8 folds in both mRNA  and 
protein levels during tumorigenesis of the prostate. Also, HER2/neu expression  could be detected in  
prostatic intraepithelial neoplasia (PIN) ,It affects androgen receptor function  and the progression of 
prostatic cancer and the determination of Association between HER2/neu and α-methylacyl coemzyme A 
racemase (AMACR) overexpressions in prostatic cancer as prognostic factors. This study  included 50 
patients aged from 50- < 70 years and 10 healthy men as control group matched with patient group ages. 
Then,  paraffin-embedding procedure was prepared on   tissues biopsy and then, hematoxylin and eosin 
staining (H. and E. staining) procedure was done . Finally, immunohistochemical procedure is done on both 
control cases and prostate cancer blocks. This immunohistochemical procedure detects her2/neu  and 
AMACR overexpression according to  DAKO protocol scoring system. The study showed that there is no 
significant difference in ages (P >0.05) between prostatic cancer patient and control group (68.46±6.26 
years , 62.79±8.68 years)  respectively and the prostatic cancer is more prevalence in ages >69 years old 
which represent 56% of cases.  
 Also, the overexpression of AMACR  represent  weak positive  (46%), moderate positive   (34%), 
strong (20%) overexpressions. While, the overexpression of HER2/neu  gives  weak positive   (60%),  
strong positive (40%) and the death occurred to 50% of prostatic cancer patient that have strong positive 
HER2/neu overexpression.  Those whose  ages are more than 69 years old who have liability for prostatic 
cancer . Immunohistochemical overexpressions of  α-methylacyl coemzyme A racemase enzyme and 
HER2/neu have prognostic marker for prostatic cancer . 
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ةصلاخلا  
تاتسوربلا ناطرس  زيمتي يذلا ثيبخ مرو وى ميزنا عافتراب(AMACR)   رادقمب7-8 فعض  ىوتسم عافترا اضياو  يعيبط نع
( يوارشبلا ومنلا لماعHER2/neuيف ةرايظلا لخاد ؤشنتلا يف دجو يذلا ) قتسم ةيفيظو ىمع رثؤيو تاتسورب يف مدقتو نيجوردنا لب
تاتسوربلا ناطرس ضرم .  ديدحت( يوارشبلا ومنلا لماع نيب ريباعتلا ةقلاعHER2/neu( ميزناو )AMACR تاتسوربلا  ناطرس يف )
 تممش ةساردلا هذى .ناطرسلا نيكتل لماوعك05 ( نيب مىرامعا حوارتت نيذلا اضيرم05- ≥75 عم ةنس )05  ضرملا نم نيميمس صاخشا
 غبصت مث يتلاو جيسنلا ةعزخ  نم نيفارابلا سيمغت ةيممع ريضحت متت مث .ناطرسلا ىضرم ةعومجم رامعا عم ةمجسنم ةنراقم ةعومجمك
( نيميسكوتاميى و نيزويلاا ةغبصبH. and E. ةقيرط ,اريخا. )يئايميك يجيسنلا يعانملا صحفلا ضرمل نيفارابلا تاكومب ىمع يرجت ى
 صاخشلااو تاتسوربلا ناطرسلا ةقيرط  . نيميمسيئايميك يجيسنلا يعانملا صحفلا  ومنلا لماع نم لكل ريباعتلا جئاتن يطعت
(يوارشبلاHER2/neu( ميزناو )AMACR( وكاد لوكوتورب ماظنل اقفو  )DAKO.)  رامعا نيب ةقلاع  دجوت لا ونا ةساردلا هذى تنيب
 نيباصملا صاخشلااب ناطرستاتسوربلا ((68.46±6.26 years  نيميمسلا صاخشلاا و( 62.79±8.68 years)  وى تاتسوربلا ناطرسو
 رثكلأااراشتنا  نم ربكا يى يتلا رامعلاا يف99  لثمت يتلاو ةنس09  ريبعت ,اضيأو . ةيضرملا تلااحلا نم %( ميزناAMACR لثمي  )
 ةبسنب بجوم فيعض69 ةبسنب بجوم طسوتمو %46م يوق و % بجو05 لثمي امنيب %  ريبعت(يوارشبلا ومنلا لماعHER2/neu لثمي )
 ةبسنب بجوم فيعض95 بجوم يوق و  %65 ىلا دتمي ىضرممل ةافولا تلااحو %05 نيذلا تاتسوربلا ناطرس ىضرم تلااح نم %
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 نم ربكا يى يتلا رامعلاا. يوارشبلا ومنلا لماعل بجوم يوق  ليمحت مييدل99 ا ةيمباق مييدل ةنس ريباعت  .  تاتسورب ناطرسب ةباصلا
يئايميك يجيسنلا يعانملا صحفلا (يوارشبلا ومنلا لماع نم لكل ريباعتلا جئاتن يطعتHER2/neu( ميزناو )AMACR ةقلاع اييدل  )
. تاتسوربلا ناطرسل نيكت 
 
تاممكلا :ةيحاتفملاا ( يوارشبلا ومنلا لماع , تاتسوربلا ناطرسHER2/neu)  ميزنا ,(AMACR ةقيرط , ) يجيسنلا يعانملا صحفلا
يئايميك .  
 
Introduction 
       Prostatic cancer is very common malignancy in the men and represents about one 
third of all male cancers. So, it is the second cause of cancer death in United State of  
America (Woods et al., 2010) and causes  27450 deaths in 2015
 
(American cancer 
society, 2015) and it represents the seventh most common cancer in Iraqi males and 
represent 5.06%  of  total cancers 
 
(Ministry of health, 2011). Prostatic cancer is most 
prevalence malignancy in males in western country but its incidence and mortality rates is 
lower in Asian countries (Kimura, 2012). The incidence of prostatic cancer in African 
Americans  is about 60% and this incidence is increased in non-Hispanic whites for 
unclear reasons. The prostatic cancer death rates  decreases for all races due to early 
detection of prostatic cancer by using prostate specific antigen (American cancer society , 
2014). 
       Prostatic cancer is heterogeneous disease with different degrees of aggressiveness, 
metastasis pattern , and response to therapy,  Prostatic cancer is caused by  complex 
etiology that includes exogenous factors( diet, environment etc.) and endogenous factors 
(hormonal imbalance, family history)  . Also, the age is risk factors and it is rare below 
the age of 40 years but it is commonly  after 60-70 years old (60% of cases are found 
over 65 years ) (Woods et al., 2010) . The pathogenesis and progression  of  prostatic 
cancer takes years and may be decades to turn from normal epithelial to premalignant to  
finally become prostatic cancer . 
       Generally, there are only few signs and symptoms in early stages of prostatic cancer  
but lower urinary tract symptoms(like urinary frequency and hesitancy, urgency and 
difficulty in   urine out flow) occur in locally advanced cases
 
(Hsiao et al., Walsh et al., 
2007). The elevation of prostatic specific antigen  with abnormal rectal examination is the 
most common diagnostic tools to detect prostatic cancer
 
(Robert, 2004). Prostatic specific 
antigen  is most useful marker for prostatic cancer due to its tissue specificity and it can 
be used for diagnosis , screening, and monitoring patient with prostatic cancer (Ulmert et 
al., 2012).       
    AMACR gene is located in chromosome 5q13 and encode a 382 amino acid protein 
that plays role in bile acid and β oxidation of branched chain fatty acids (Streekumer et 
al.,2004). The expression of AMACR protein is regarded as new diagnostic marker for 
prostatic cancer and specially in case of needle biopsies when quantity and quality of 
tissue are limited (Xu et al.,2014) . Zha et al., 2003 study has demonstrate a that the 
increase level of AMACR expression in  prostatic cancer  leads to proliferation of the 
cells and this is independent of androgen action. 
    HER2/neu is a member of the receptor (also called erbB2 ) and it is transmembrane 
glycoprotein that contains intrinsic tyrosine kinase  activity (Schreoder et al., 2014). 
HER2 gene is located in chromosome 17q21 and its amplification was discovered  in 
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several tumors . So and expression of HER2/neu was found in prostatic intraepithelial 
neoplasia , affected androgen receptor (that play important role in growth of prostatic 
cancer and maintained the libido) , and progression of prostatic cancer (Kankaya et 
al.,2008). 
   Signoretti et al. , 2000 showed 60% of prostatic cancer are associated with HER2 
amplification and/or overexpressed , the sensitivity of fluorescent in situ hybridization to 
HER2 amplification was lower in prostatic cancer (10%-25% ) compared with other 
types of malignancies (Kankaya et al.,2008). 
     
Methods  
 This  study was conducted in Al-Hariri general hospital /Baghdad and Al-amel 
hospital /Baghdad , the period of study  extended from Septemer /2012 to May/2014. 
clinical data of patients  include age, sex , and clinical features are taken with paraffin 
blocks .The practical side of the study was done  in Al-Hilla governorate and  at 
Baghdad/ Biotechnology Research Center/ Al-Nahrin University . This study  included 
50 patient with prostate  cancer  with   10 control . 
The prostate paraffin block tissues were taken through radical removal of prostate 
or biopsy via ultrasound  ultrasound   guided needle biopsy. 
Then,  paraffin-embedding procedure was prepared on   tissues biopsy and then, 
hematoxylin and eosin staining (H. and E. staining) procedure was done and Gleason 
grading is most commonly dependent scale that used for prostate cancer grading system 
which based on histological features of the tumor. Finally,   immunohistochemistry is 
done on both control cases  and prostate cancer blocks. This immunohistochemistry  
method detects her2/neu and AMACR expression according to DAKO scoring system. 
      DAKO scoring system of HER2/neu uses the following categories : 0 is negative 
result or membrane staining in < 10% of the tumor cells, 1+ is weak and incomplete 
membrane staining in > 10% of the tumor cells , 2+ is weak to moderate, complete 
membrane staining in > 10% of the tumor cells , and 3+ is strong  complete membrane 
staining in > 10% of the tumor cells (Lara et al.,2002)
  
. 
 The negative and 1+ indicate normal HER2/neu expression, 2+ indicate intermediate 
cases that to be proved by another method (fluorescent in situ hybridization ), 3+ shows 
HER2/neu overexpression. 
      While, A scale of AMACR are ranging from 0 to 3 was used to grade the expression. 
 0 indicates no expression , 1(up to 50% of cells with detectable staining) gives weak 
expression , 2 ( 50%  to 75% of cells with moderate staining) indicate  intermediate 
staining and 3 (more than 75% of cells with intense staining)  shows strong expression 
(Troung et al., 2008). 
Results 
 There is no difference (P >0.05) in the mean of ages between prostatic cancer 
patient and control group (68.46±6.26 years , 62.79±8.68 years) respectively. The 
minimum age in patients and control group are 58 years and 50 years respectively while 
The maximum age in both patients and control group are 80 years  as in table (1)  . 
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Table (1): The age of prostatic cancer patients and control group. 
 
patients   group control group Age/years 
68.46±6.26 62.79±8.68 Mean±SD 
58 50 minimum 
80 80 maximum 
 
       The prostatic cancer is more prevalence in age group > 69 years that represents 56% 
of patients , followed by age groups 60-69 years and 50-59 years which give 38%  and 
6% respectively as in figure (1). There are no significant differences (P >0.05) between 
ages in prostatic cancer prevalence . 
 
    
 
Figure (1): Age prevalence in prostatic cancer patients. 
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Table (2):  Association between Gleason grade levels with histopathological types, 
HER2/neu, and AMACR overexpressions. 
 
The  Table (3) shows that there is weak overexpression of α-methylacyl COA 
racemase in 23 patients that represent 46% of all prostatic cancer patients. Moderate 
overexpression   in AMACR is 17 patients that correspond to 34% of all prostatic cancer 
patients. Strong overexpression   in AMACR is 10 patients that correspond to 20% of all 
prostatic cancer patients.   
 
 
 
 
 
Variables  
 
number of patients Gleason grade levels 
Gleason grades level according to  
histopathological types 
 
   
 
 
12 
10 
16 
10 
2   
 
   10 
   9 
   8 
   7 
   6 
Gleason grades level according to    
HER2/neu overexpression 
  
Strong  HER2/neu overexpression 
 
 
 
Weak  HER2/neu overexpression 
 
 
 
 
2 
 
 
 
10 
 
2 
1 
 
7 
8 
Gleason grades level according to    
AMACR overexpression 
  
Weak   AMACR overexpression 
 
 
 
Moderate AMACR overexpression 
 
 
 
 
Strong   AMACR overexpression 
 
 
 
10 
7 
6 
 
 
8 
9 
10  
 
9 
4 
3 
1 
 
6 
7 
9 
10 
 
5 
3 
1 
1 
 
6 
7 
8 
9 
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Table (3): The number of overexpressed prostatic cancer patients to α-methylacyl 
COA racemase and  HER2/neu . 
overexpression Gene 
Strong positive Moderate positive Weak positive 
% number % number % number 
20 10 34 17 46 23   α-methylacyl COA 
racemase 
40 2 - - 60 3 HER2/neu  
  
  In table (3), there is weak positive overexpression of HER2/neu in 3 patients that 
represent 60% of all prostatic cancer patients. Strong overexpression of HER2/neu is 2 
patients that represent 40% prostatic cancer patients. There are 5 prostatic cancer patients 
diagnosed with HER2/neu that represent 10% from 50 prostatic cancer patients. 
  
Table (4): The percentage  of   prostatic cancer patients diagnosed with 
  α-methylacyl COA racemase and HER2/neu overexpressions . 
overexpression Gene 
percentage number 
100% 50 α-methylacyl COA 
racemase 
10% 5 HER2/neu 
 
 
A number of deceased prostatic cancer patients occurs in one patient from the total five 
patients of prostatic cancer . The deceased patients have  been diagnosed with strong 
overexpression of HER2/neu that represent 20% of the total patients diagnosed with 
HER2/neu as in table (5) .  
 
Table (5): The percentage  of   prostatic cancer deaths in  overexpression  of α-
methylacyl COA racemase and HER2/neu . 
percentage Number of deceased 
patients 
Gene 
0% 0 α-methylacyl COA 
racemase 
20% 1 (HER2/neu) 
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Figure (2): Positive HER2/neu in prostatic cancer (adenocarcinoma) by 
immunohistochemistry stain (40X) : (A) Intensity 3+,   well differentiation Gleason 
score 4/10, and arrows  refer to stained membrane cancer cells, (B) Intensity 
2+,moderate differentiation Gleason score 4/10, and arrows  refer to stained 
membrane cancer cells 
 
 
 
 
 
 
 
 
 
 
 
 
B 
A 
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Figure (3): Positive AMACR in prostatic cancer (adenocarcinoma) by 
immunohistochemistry stain (40X) : (A) Intensity 3+,   well differentiation Gleason 
score 5/10, and arrows  refer to stained intracytoplasmic  cancer cells, (B) Intensity 
3+,moderate differentiation Gleason score 6/10, and arrows  refer to stained 
intracytoplasmic  cancer cells. 
 
Discussion 
       The results of this study demonstrate that the prostatic cancer is more common in 
ages >69 years and there was no significant difference ( P > 0.05) in the prostatic cancer 
incidence in the ages between the subjects in the control group and these in the 
experimental group. The data of our trail showed that the ages > 69 years represent 56% 
of all prostatic cancer patients .  
       Ages 60-69 years represent 38% of all prostatic cancer patients and then the age 50-
59 years that represent 6% and this ratio constitutes the lowest percentage in the prostatic 
cancer patients in this study.  
      All researchers like Gronberg (Gronberg,2003) , Leitzmann and Rohrmann 
(Leitzmann and Rohrmann, 2012),  and Romero et al (Romero et al.,2012 considering  
A 
B 
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age as non-modifiable risk factors for prostatic cancer  agree that age is the important risk 
factors for  prostatic cancer . The current trail  coincide that age has many features to get 
the priority in prostatic cancer proposed that the hydroxyl radical assist   changes in the 
structure that resemble the cancer-like phenotype (Malins et al.,2003). 
      There is ratio of mutagenic 8-hydroxyl to non-mutagenic purine lesion in prostate 
deoxyribonucleic acid (DNA) that increased 3-folds in old men than it is the case with     
the young men in addition to  an increase in base oxidation . 
    The increase in DNA base lesion concentrate in various tissues , reduced enzyme 
repair deoxyribonucleic acid nuclease activity, all the finding with age related changes 
has important role in prostatic development (De Pinho,2000;  Brosh et al.,2001; Osterod 
et al.,2001)  . We supposed that older men have greater  chance to get prostatic cancer 
because they have more exposure to exogenous effects like (diets, smokes, chemicals) 
and endogenous effects like (free radical, hormonal imbalance) that leads to more lesion 
for DNA and its repair system. 
    The diagnosis of prostatic cancer is based on combination of architectural, cytological 
and additional features (Kumaresan et al.,2010). The diagnosis can be difficult due to the 
presence of either a small focus of cancer or due to the many benign mimickers of 
malignancy like , adenosis atrophy , partial atrophy , basal cell hyperplasia . In this study,  
we collected many suspected tissue microarrays with prostatic cancer from the 
laboratories of Al-Hariri general hospital according to pathologist reports, but all these 
tissue microarrays give positive result for prostatic cancer when it stained with AMACR 
by immunohistochemistry (IHC) . Our judgement for that result, is that the AMACR 
(IHC) is more sensitive than hematoxylin and eosin (H and E stain) in prostatic cancer 
diagnosis . We cannot find tissue mimicked to prostatic cancer to compare H and E stain 
with AMACR stain to evaluate accuracy in detection of prostatic cancer. This study 
showed the deceased percentage is 0% in strong positive overexpression of AMACR . 
     The most important explanation to this result of the AMACR overexpression is  the 
decreased in hormone-refractory metastatic tissue sample compared to localized prostatic 
cancer (Kuefer,2002), so strong positive overexpression of AMACR has no relationship 
to death. 
    Expression  of HER2/neu was shown in the cells membrane and detected by 
immunohistochemistry  technique depending on the scoring system used for the 
HER2/neu . Alteration in HER2/neu  overexpression as tumor progresses from localized 
to metastatic   cancer and from androgen dependence to androgen independence  . When 
hormone-refractory occusr , treatment is limited ,  the prognosis is poor, and most 
patients will die within 9-12 month (Carles et al., 2004). The result of our study showed 
that one men with prostatic cancer deceased as a result of HER2/neu overexpression and 
might have hormone-refractory. Data  showed positive overexpression for HER2/neu was 
found in 20% of  prostatic cancer patients while 80% cases were not expressed or were 
negative for HER2/neu depending upon cutoff value . Death occurred in one patient who 
has diagnosed with HER2/neu  overexpression by immunohistochemistry and this finding 
is supported by another researches that the prostatic cancer patients   HER2 gene is bad 
prognosis (Carles et al., 2004).   
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Conclusion 
HER2/neu  overexpressions is associated with high Gleason score .HER2/neu 
overexpressions are  regarded as bad prognostic factor. α-methylacyl coemzyme A 
racemase (AMACR) overexpressions is associated with low Gleason score . α-methylacyl 
coemzyme A racemase (AMACR)  overexpressions are regarded   good prognostic 
factor.  
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